Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bausch Health Companies Inc

Bausch Wins US Appeal Blocking Alvogen Diarrhea Drug Generic

Bausch Health Companies Inc. secures legal victory in US appeal court case, protecting patent for popular diarrhea drug.

3 Pharma Stocks to Buy for February Gains

3 Pharma Stocks to Buy for February Gains

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

Meta, Charter Communications, Southwest Airlines And Some Other Big Stocks Moving Lower On Thursday

Meta, Charter Communications, Southwest Airlines And Some Other Big Stocks Moving Lower On Thursday

Bausch Health Companies Inc. (NYSE: BHC) shares fell 50.3% to $4.3166 following reports of an order on a patent litigation over Xifaxan.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Cramer Gives His Opinion On Equinix, Bausch Health And More

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Bausch Health Companies Inc.

Bausch Health's Q1 Sales, Profits Fall On Supply Chain Challenges, Cuts FY22 Outlook

Bausch Health Companies Inc (NYSE:BHC) has reported Q1 revenues of $1.92 billion, down 5% Y/Y. Excluding the unfavorable impact of foreign exchange of $41 million and divestitures & discontinuations of $72 million, revenue was flat organically compared to Q1 FY21. Adjusted net income declined to $263 million from $370 million a year…

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816 million; consensus $819 million).

Scoop Up These 4 Buy-Rated Healthcare Stocks Trading Near 52-Week Lows

Despite the prevailing bearish investor sentiment, the healthcare industry is expected to continue growing amid an increase in global chronic diseases, rapid medical advancements, and an aging population. The stocks of quality healthcare companies Bausch Health (BHC), Teleflex (TFX), Abcam (ABCM), and Integra LifeSciences (IART) are currently trading near their…

inkl

Read news from The Economist, FT, and more,
with one subscription

Closely Watched Bausch + Lomb IPO Priced Below Expectations

Closely Watched Bausch + Lomb IPO Priced Below Expectations

Bausch + Lomb Corp (NASDAQ:BLCO) has priced its initial public offering at $18/share, falling short of expectations as it became the first big company in months to try going public in a turbulent stock market, writes Wall Street Journal. Bausch Health Companies Inc (NYSE:BHC), the parent company, raised $630 million in the offering. According to…

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View

Bausch Health Companies Inc (NYSE: BHC) has reported

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

Medical Pharmaceuticals

RBC Capital Markets

ACADIA Pharmaceuticals Inc

Medical – Devices & Equipment

Bausch Health Companies

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

244,099 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play